Compare Campbell Soup Co. (CPB) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Charles River Laboratories Intl. Inc — how do they compare? Campbell Soup Co. trades at $22.43 (market cap $6.78B), while Charles River Laboratories Intl. Inc trades at $285.14 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Campbell Soup Co. pays a 6.87% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CPB | CRL | |
|---|---|---|
Market Cap | $6.78B | $13.46B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $282.00 |
52-Week Low | $20.00 | $145.57 |
Enterprise Value | $13.38B | $16.30B |
Dividend Yield | 6.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.42, down 2.73% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of $0.50, beating expectations of $0.4789, while Q4 2025 missed estimates. Revenue reached $10.25B in 2025 with a net income margin of 6.12%, though profitability metrics like ROE (3.09%) remain modest. Recent news highlights product innovation with new protein soups and leadership transitions aimed at business transformation.
The outlook for CPB is cautious with a consensus price target of $20.20 below the current price, reflecting analyst skepticism (58.62% Hold, 37.93% Sell). Opportunities include cost-saving initiatives and a sustainable ~7% dividend yield, but risks involve margin pressures, high debt levels, and competitive challenges in the packaged foods sector. Investors should weigh the dividend appeal against structural profitability concerns.
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
